October 1, 2019

Taisho and Moberg Pharma sign exclusive license agreement for the development and commercialization of MOB-015 in Japan

Taisho Pharmaceutical Co., Ltd. (“Taisho;” headquarters: Toshima-ku, Tokyo; CEO: Shigeru Uehara) has announced that Taisho and Moberg Pharma AB (“Moberg;” headquarters: Stockholm, Sweden; CEO: Anna Ljung), signed an agreement on the exclusive development and sales of MOB-015 (topical formulation of 10% terbinafine) for the treatment of onychomycosis in Japan. Under this agreement, Taisho will conduct the development, acquisition of marketing authorization and sales of MOB-015 as an ethical drug, and Moberg will receive upfront payment and milestone payments from Taisho.

Terbinafine has been used for the treatment of diseases such as ringworm for a long time. MOB-015 is a promising agent developed as a highly concentrated terbinafine topical formulation that overcomes conventional issues based on Moberg's patented proprietary formulation technology. Moberg is currently conducting Phase 3 clinical trials for patients with onychomycosis in North America and Europe.

Onychomycosis is a disease caused by a ringworm fungal infection of the nail. Although 10% of Japanese population are estimated to be affected, many patients are believed to be untreated. Compared to healthy individuals, the elderly and diabetic patients are particularly known to have a higher incidence of onychomycosis, highlighting the importance of treatment.

Moberg is a Swedish pharmaceutical company that focuses on the development of pharmaceuticals using its proprietary innovations. It is headquartered in Stockholm and is listed on the NASDAQ OMX Nordic Exchange Stockholm (OMX: OMB). For more information, visit Moberg’s website (http://www.mobergpharma.com).

Through the development of MOB-015, Taisho seeks to provide more patients with a new treatment option for onychomycosis.